Neutra Corp. (NTRR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 52.18 Thousand USD | 0.0% |
| 2023 | 52.18 Thousand USD | -78.13% |
| 2022 | 238.65 Thousand USD | 10.28% |
| 2021 | 216.4 Thousand USD | 60.06% |
| 2020 | 135.2 Thousand USD | -68.24% |
| 2019 | 425.65 Thousand USD | 180.84% |
| 2018 | 151.56 Thousand USD | 79.06% |
| 2017 | 84.64 Thousand USD | 390.23% |
| 2016 | 17.26 Thousand USD | -62.23% |
| 2015 | 45.7 Thousand USD | -65.2% |
| 2014 | 131.33 Thousand USD | 5409.02% |
| 2013 | 2384.00 USD | -87.01% |
| 2012 | 18.35 Thousand USD | 283.53% |
| 2011 | -10 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 51.01 Thousand USD | -2.24% |
| 2024 FY | 52.18 Thousand USD | 0.0% |
| 2024 Q2 | 53.02 Thousand USD | 3.93% |
| 2024 Q3 | 53.46 Thousand USD | 0.83% |
| 2024 Q4 | 52.18 Thousand USD | -2.39% |
| 2023 Q1 | 281.32 Thousand USD | 17.88% |
| 2023 Q2 | 270.18 Thousand USD | -3.96% |
| 2023 FY | 52.18 Thousand USD | -78.13% |
| 2023 Q4 | 52.18 Thousand USD | -82.21% |
| 2023 Q3 | 293.41 Thousand USD | 8.6% |
| 2022 Q1 | 232.29 Thousand USD | 7.34% |
| 2022 Q4 | 238.65 Thousand USD | 13.29% |
| 2022 Q3 | 210.65 Thousand USD | -15.69% |
| 2022 FY | 238.65 Thousand USD | 10.28% |
| 2022 Q2 | 249.85 Thousand USD | 7.56% |
| 2021 Q2 | 179.92 Thousand USD | -30.77% |
| 2021 FY | 216.4 Thousand USD | 60.06% |
| 2021 Q3 | 226.23 Thousand USD | 25.74% |
| 2021 Q4 | 216.4 Thousand USD | -4.35% |
| 2021 Q1 | 259.9 Thousand USD | 92.24% |
| 2020 Q1 | 465.06 Thousand USD | 9.26% |
| 2020 Q3 | 306.15 Thousand USD | -20.41% |
| 2020 FY | 135.2 Thousand USD | -68.24% |
| 2020 Q4 | 135.2 Thousand USD | -55.84% |
| 2020 Q2 | 384.66 Thousand USD | -17.29% |
| 2019 Q2 | 235.4 Thousand USD | 108.87% |
| 2019 Q3 | 222.79 Thousand USD | -5.36% |
| 2019 Q4 | 425.65 Thousand USD | 91.05% |
| 2019 FY | 425.65 Thousand USD | 180.84% |
| 2019 Q1 | 112.7 Thousand USD | -26.77% |
| 2018 Q2 | 119.08 Thousand USD | 180.79% |
| 2018 Q3 | 116.49 Thousand USD | -2.17% |
| 2018 Q4 | 153.89 Thousand USD | 32.1% |
| 2018 FY | 151.56 Thousand USD | 79.06% |
| 2018 Q1 | 42.41 Thousand USD | -49.9% |
| 2017 Q3 | 82.78 Thousand USD | 56.62% |
| 2017 Q4 | 84.64 Thousand USD | 2.24% |
| 2017 FY | 84.64 Thousand USD | 390.23% |
| 2017 Q1 | 19.97 Thousand USD | 15.68% |
| 2017 Q2 | 52.85 Thousand USD | 164.65% |
| 2016 Q1 | -2172.00 USD | -104.75% |
| 2016 FY | 17.26 Thousand USD | -62.23% |
| 2016 Q4 | 17.26 Thousand USD | 184.82% |
| 2016 Q3 | 6062.00 USD | -40.57% |
| 2016 Q2 | 10.2 Thousand USD | 569.66% |
| 2015 Q1 | 141.85 Thousand USD | 8.01% |
| 2015 Q4 | 45.7 Thousand USD | -75.32% |
| 2015 FY | 45.7 Thousand USD | -65.2% |
| 2015 Q3 | 185.18 Thousand USD | -30.18% |
| 2015 Q2 | 265.22 Thousand USD | 86.97% |
| 2014 Q4 | 131.33 Thousand USD | 2181.71% |
| 2014 FY | 131.33 Thousand USD | 5409.02% |
| 2014 Q1 | -122.69 Thousand USD | -5246.69% |
| 2014 Q2 | -204.34 Thousand USD | -66.55% |
| 2014 Q3 | -6309.00 USD | 96.91% |
| 2013 Q4 | 2384.00 USD | 427.02% |
| 2013 FY | 2384.00 USD | -87.01% |
| 2013 Q2 | -5287.00 USD | -105.56% |
| 2013 Q3 | -729.00 USD | 86.21% |
| 2013 Q1 | 95.16 Thousand USD | 418.54% |
| 2012 Q2 | -30.04 Thousand USD | -374.32% |
| 2012 Q4 | 18.35 Thousand USD | 169.3% |
| 2012 FY | 18.35 Thousand USD | 283.53% |
| 2012 Q3 | -26.48 Thousand USD | 11.87% |
| 2012 Q1 | -6335.00 USD | 0.0% |
| 2011 FY | -10 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 4083.74% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 99.076% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.878% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 120.907% |
| Rebus Holdings, Inc. | 305 Thousand USD | 82.89% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 100.828% |
| Qrons Inc. | 351.42 Thousand USD | 85.15% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 91.615% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.88% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 355.718% |
| Skye Bioscience, Inc. | -5.72 Million USD | 100.912% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 99.669% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 98.733% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 87.013% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.144% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 97.673% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 94.371% |
| Mesoblast Limited | 55.85 Million USD | 99.907% |
| Marizyme, Inc. | 18.56 Million USD | 99.719% |
| Genus plc | 190.6 Million USD | 99.973% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 97.666% |
| Pharming Group N.V. | 109.8 Million USD | 99.952% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 93.933% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 95.701% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 92.325% |
| ContraFect Corporation | -6.02 Million USD | 100.866% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 61.239% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 95.483% |
| IMV Inc. | 7.67 Million USD | 99.32% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 99.051% |
| MultiCell Technologies, Inc. | 90.04 USD | -57859.796% |
| ONE Bio Corp. | 9.04 Million USD | 99.423% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 107.11% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 99.597% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 96.185% |
| Q BioMed Inc. | 4.06 Million USD | 98.715% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.829% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 94.821% |
| Biomind Labs Inc. | 711.4 Thousand USD | 92.664% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.914% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 97.39% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 99.592% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 85.492% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 62.671% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -162.682% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 97.63% |
| GB Sciences, Inc. | 1.74 Million USD | 97.013% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 128.395% |
| HST Global, Inc. | 96.79 Thousand USD | 46.084% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 74.693% |
| Halberd Corporation | 144.72 Thousand USD | 63.94% |
| Enzolytics Inc. | 981.65 Thousand USD | 94.684% |
| Agentix Corp. | 37.63 Thousand USD | -38.681% |
| Resverlogix Corp. | 6.45 Million USD | 99.191% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 107.753% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.003% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.111% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 99.262% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 98.073% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 100.59% |
| AVAX Technologies, Inc. | -5.9 Million USD | 100.884% |
| Zenith Capital Corp. | 10.06 Thousand USD | -418.551% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.005% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 73.963% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 97.813% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 68.277% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 384.895% |
| Kadimastem Ltd | -253.1 Thousand USD | 120.619% |
| Helix BioMedix, Inc. | -2.57 Million USD | 102.031% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 99.743% |
| BioStem Technologies, Inc. | 4.47 Million USD | 98.833% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 74.069% |
| LadRx Corporation | -2.03 Million USD | 102.563% |
| Cell Source, Inc. | 9.23 Million USD | 99.435% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 91.784% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 91.784% |
| NovAccess Global Inc. | 2.17 Million USD | 97.604% |
| Affymax, Inc. | -5.59 Million USD | 100.932% |
| Itoco Inc. | 228.3 Thousand USD | 77.142% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 61.624% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 98.947% |
| Mobile Lads Corp. | 484.23 Thousand USD | 89.223% |
| CytoDyn Inc. | 20.26 Million USD | 99.742% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 8165.997% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 663.067% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 99.323% |
| SYBLEU INC | 473.71 Thousand USD | 88.983% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 98.829% |
| International Stem Cell Corporation | 2.59 Million USD | 97.985% |
| Bioxytran, Inc. | 1.89 Million USD | 97.252% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 16.384% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 97.607% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 98.48% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 99.39% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 93.245% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 104.175% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 102.097% |
| PureTech Health plc | -167.19 Million USD | 100.031% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 121.309% |
| IXICO plc | -4.44 Million USD | 101.174% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 99.605% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.905% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 100.119% |